Cholestasis Clinical Trial
Official title:
Omegaven as Alternative Parenteral Fat Nutrition
Verified date | July 2019 |
Source | University of South Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis
Status | Completed |
Enrollment | 2 |
Est. completion date | January 7, 2019 |
Est. primary completion date | January 7, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Greater than 14 days old - Has parenteral nutrition associated cholestasis defined as at least 2 consecutive direct bilirubin >2 mg/dL with anatomical or functional short gut (OR >4 mg/dL if intact intestine) obtained at least 1 week apart with a ratio of direct: total bilirubin > 0.4 - Patient is parenteral nutrition dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require parenteral nutrition for at least 3 more weeks - Patient has not responded to other therapeutic approaches for parenteral nutrition-associated liver disease such as : cycling of parenteral nutrition, avoiding overfeeding, reduction/removal of copper and manganese from parenteral nutrition, advancement of enteral feeding, and use of Ursodiol - Patient has been on at least 2 weeks of SMOFLIPIDs with no improvement or worsening of direct bilirubin levels - Signed patient informed consent - The patient is expected to have a reasonable possibility of survival - No other known etiology of cholestasis other than parenteral nutrition-associated liver disease at the time of Omegaven® initiation Exclusion Criteria: - Known causes of cholestasis other than parenteral nutrition-associated liver disease including but not limited to Hepatitis C, Cystic fibrosis, biliary atresia, and alpha 1 antitrypsin deficiency are present, prior to Omegaven® initiation - Known fish or egg allergy - Any of the contraindications to use of Omegaven®: 1. Active new infection at the time of initiation of Omegaven® 2. Hemodynamic instability 3. Recent use of medications with associated risk of bleeding, including NSAIDs 4. Active coagulopathy or bleeding 5. Platelet counts persistently under 30,000 despite transfusions 6. Unstable hyperglycemia 7. Impaired lipid metabolism (triglycerides >1000 mg/dL) while on 1 g/kg/day or less of Intralipid 8. History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease, etc.) 9. Unstable diabetes mellitus 10. Collapse and shock 11. Stroke/ Embolism 12. Cardiac infarction within the last 3 months 13. Undefined coma status |
Country | Name | City | State |
---|---|---|---|
United States | USF Health | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
University of South Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participant With Decrease in Direct Bilirubin Level | Number of participant with decrease in direct bilirubin levels within 30 days of treatment | First month of treatment | |
Secondary | Number of Participant With Resolution of Direct Hyperbilirubinemia | Number of participant with Direct bilirubin level of <2mg/dL at discontinuation of treatment | 2 months | |
Secondary | Number of Participant With Preservation of Length | Monitoring of weekly length while the patient is receiving Omegaven® treatment | Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment | |
Secondary | Number of Participant With Preservation of Head Circumference | Monitoring of weekly head circumference while the patient is receiving Omegaven® treatment | Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment | |
Secondary | Number of Participant With Preservation of Normal Weight Gain | Monitoring of daily weight gain while the patient is on Omegaven® | Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Completed |
NCT00738101 -
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
|
N/A | |
Completed |
NCT00004414 -
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
|
N/A | |
Recruiting |
NCT02334293 -
Omegaven® as Parenteral Nutrition
|
N/A | |
Recruiting |
NCT01252043 -
Retrospective Review of CT and MR in Pediatric Patients With Cholestasis
|
N/A | |
Completed |
NCT00846963 -
Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
Completed |
NCT01194063 -
Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
|
Phase 3 | |
Recruiting |
NCT01998620 -
Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
|
Phase 4 | |
Completed |
NCT00080236 -
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
|
Phase 2 | |
Completed |
NCT00058890 -
Gabapentin to Treat Itch in Patients With Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT00004315 -
Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT02922751 -
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
Completed |
NCT04604652 -
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
|
Phase 2 | |
Terminated |
NCT02267707 -
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
|
Phase 1 | |
Completed |
NCT02357576 -
Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
|
Phase 3 | |
Completed |
NCT02721277 -
SMOFlipid to Lessen the Severity of Neonatal Cholestasis
|
Phase 1/Phase 2 | |
Terminated |
NCT02767648 -
Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region
|
N/A | |
Completed |
NCT01073202 -
Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation
|
N/A |